FDA Approves New Drug for Resistant TB

2019-08-14 |

The FDA has approved Pretomanid in combination with bedaquiline and linezolid for treating a limited and specific population of adult patients with extensively drug resistant, treatment-intolerant or nonresponsive multidrug-resistant pulmonary tuberculosis (TB). Multidrug-resistant TB and extensively drug-resistant TB are difficult to treat due to resistance to available therapies. This treatment should not be used in patients with hypersensitivity to bedaquiline or linezolid. For more information read the FDA news release.